LONG-TERM CONTROLLED CLINICAL TRIAL ON A NEW ANTI-INFLAMMATORY DRUG - DIFTALONE - IN RHEUMATOID ARTHRITIS

Abstracts ◽  
1977 ◽  
pp. 258
Author(s):  
Valentin Stroescu ◽  
Carmen Georgescu ◽  
Radu Voiosu
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Inflammatory Drug ◽  
Anti Inflammatory

A Controlled Clinical Trial of a New Anti-Inflammatory Drug, Diftalone, in Rheumatoid Arthritis

1974 ◽  
Vol 2 (5) ◽  
pp. 338-346 ◽  
Author(s):  
Valentin Stroescu ◽  
Carmen Georgescu ◽  
Radu Voiosu
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trial ◽  
Randomized Trial ◽  
Term Treatment ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Inflammatory Drug ◽  
Long Term Treatment ◽  
Anti Inflammatory

In a double-blind, randomized trial on thirty-two patients affected by classical or definite rheumatoid arthritis, we have tried the effectiveness and safety of 500 mg/day oral diftalone versus 75 mg/day oral indomethacin for a period of six to twelve months treatment. Diftalone proved to be an effective and well tolerated anti-inflammatory drug in long-term treatment of rheumatoid arthritis. Its activity and safety is at least comparable to that achieved by the use of indomethacin.

Bisphosphonate Increases Risk of Peptic Ulcer in Rheumatoid Arthritis Patients On Long-Term Non-Steroidal Anti-Inflammatory Drug Therapy

2008 ◽  
Vol 67 (5) ◽  
pp. AB276
Author(s):  
Masafumi Kusunoki ◽  
Kazumasa Miyake ◽  
Mariko Umezawa ◽  
Tomotaka Shindo ◽  
Nobue Ueki ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Peptic Ulcer ◽  
Drug Therapy ◽  
Inflammatory Drug ◽  
Anti Inflammatory

scholarly journals LONG-TERM OUTCOMES IN RHEUMATOID ARTHRITIS IN RELATION TO THE TIME AFTER THE INITIATIONOF BASIC ANTI-INFLAMMATORY DRUG THERAPY

2010 ◽  
Vol 0 (3) ◽  
pp. 23 ◽  
Author(s):  
Natalya Vladimirovna Chichasova ◽  
M Z Kanevskaya ◽  
G R Imametdinova ◽  
E V Igolkina ◽  
E L Nasonov
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Therapy ◽  
Long Term Outcomes ◽  
Inflammatory Drug ◽  
Anti Inflammatory

Long-Term Controlled Clinical Trial of a New Anti-Inflammatory Drug, Diftalone, in Rheumatoid Arthritis

1976 ◽  
Vol 4 (1) ◽  
pp. 23-33 ◽  
Author(s):  
V Stroescu ◽  
C Georgescu ◽  
R Voiosu
Keyword(s):  
Rheumatoid Arthritis ◽  
Comparative Trial ◽  
Lower Number ◽  
Controlled Clinical Trial ◽  
Clinical Parameters ◽  
Double Blind ◽  
Erythrocyte Sedimentation ◽  
Number Of Patients ◽  
Anti Inflammatory

A long-term ( two years) double-blind, comparative trial of diftalone ( Aladione®) 500 mg versus indomethacin 75 mg per day, in rheumatoid arthritis ( thirty-two patients), has shown a similar effectiveness for both anti-inflammatory agents on various clinical parameters of disease activity, some better results being obtained for diftalone as regards the capacity of reducing erythrocyte sedimentation rate. The tolerability of diftalone proved to be somewhat superior, as is shown by the lower number of patients complaining of side-effects or being dropped out for intolerance, and by the lower frequency of central nervous system disturbances.

scholarly journals Anti-inflammatory effects of different statins in rheumatoid arthritis; a randomized double-blind controlled clinical trial

2019 ◽  
Vol 5 (1) ◽  
pp. e09-e09 ◽  
Author(s):  
Mansoor Karimifar ◽  
Mansour Salesi ◽  
Rasoul Ghasemian ◽  
Mozhgan Karimifar ◽  
Ziba Farajzadegan ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Anti Inflammatory

scholarly journals Effect of Guluronic Acid (G2013), As a New Anti-inflammatory Drug on Gene Expression of Pro-inflammatory and Anti-inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients

2020 ◽  
Author(s):  
Tahereh Bakhtiari ◽  
ShahinKhadem Azarian ◽  
Afshin Ghaderi ◽  
Arman Ahmadzadeh ◽  
Abbas Mirshafiey
Keyword(s):  
Rheumatoid Arthritis ◽  
Gene Expression ◽  
Clinical Trial ◽  
Transcription Factors ◽  
Inflammatory Cytokines ◽  
Inflammatory Cytokine ◽  
Inadequate Response ◽  
Inflammatory Drug ◽  
Guluronic Acid ◽  
Anti Inflammatory

Rheumatoid arthritis (RA) as a long-term autoimmune disease is characterized by pain, swelling and joints destruction. The therapeutic efficacy of Guluronic acid (G2013) (patented, DEU: 102016113017.6) was reported in phase I/II clinical trial in RA patients. In this study, we aimed to evaluate the effect of G2013 as a novel non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive property on genes expression of anti-inflammatory and pro-inflammatory cytokines and their transcription factors in the blood sample of RA patients. This study was performed on 12 patients with RA who had an inadequate response to conventional treatments which were disease-modifying anti-rheumatic drugs (DMARDs), NSAID, and biologics. G2013 was administered orally at a dose of 500 mg twice daily for 12 weeks. Before and after the treatment of patients with drug G2013, the peripheral blood mononuclear cells (PBMCs) were isolated for evaluating the gene expression level of interleukin 10 (IL10), interleukin 22 (IL22), interferon γ (IFNγ), and transcription factors specific to the T helper cell lineages, forkhead box P3 (Fox-P3), Aryl hydrocarbon receptor (AHR) and T-box–containing protein expressed in T cells (T-bet) using the real-time PCR method. Since these cytokines have a key role in the progression of RA and disease condition expected induction of IFNγ, AHR, IL22, T-bet, and reduction of IL10, Fox-P3. Results indicated a significant reduction in the level of IFNγ, AHR and a significant induction in IL10, Fox-P3 gene expression in comparison with the control group. In conclusion; the results of this investigation showed a part of the immunological mechanism of G2013 as a novel anti-inflammatory that could reduce pro-inflammatory cytokine and their transcription factors. Furthermore, it increased the anti-inflammatory cytokine and its transcription factor (clinical trial identifier: IRCT2016092813739N5).

Sign in / Sign up

Export Citation Format

Share Document